An interventional study of Renal assist device in Renal Impairment After Cardiac Surgery, Renal Impairment and Acute Kidney Injury, sponsored by 3ive Labs. Recruiting at 7 sites in 2 countries. Open to participants aged 22 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-03-19.
Sponsored by 3ive Labs · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 370 studies in Acute Kidney Injury with a site in United States — 72 open to participants now, 88 under way, 9 of them phase 3. Acute Kidney Injury · United States.
Among the 370 studies in Acute Kidney Injury with a site in United States, this one is the 84th largest by planned enrollment of the 237 interventional ones that give a count, is one of 22 that started in 2025, is one of 106 with no phase, reaches primary completion later than 22 of the 87 other live ones, and was the 338th registered.
1,692 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.
Browse Acute Kidney Injury studies →72 of the 370 studies in Acute Kidney Injury with a site in United States are open now. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 18+
University of Minnesota · Sites in United States
Ages 30–75
University of California, San Francisco · Sites in United States
Ages 18+
Bassett Healthcare · Sites in United States
Ages 18+
Dana Fuhrman · Sites in United States
Ages up to 18
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.
This study: 22 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
370 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 26 · Phase 2 69 · Phase 3 29 · Phase 4 23
First in 1999; this study’s year is marked. 22 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 124 is above the median of 100 across 819 interventional studies indexed under Acute Kidney Injury.
Median enrollment 67 across the 237 interventional studies, 124 across the 131 observational. Of the 240 that completed or were terminated, 84 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
97 of 370 have an industry lead sponsor. The 10 most frequent:
3ive Labs is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
3ive Labs has 2 studies filed under Acute Kidney Injury — fewer than ten, so there is no comparison to draw.
33 of the studies in Acute Kidney Injury with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07161843Phase 3Ebima Clifford OkundayeUse of QRX3 for Acute Tubular Necrosis Type of Renal Failure in Hospitalized Patients ( QRX-3 in ARF) | 2026-12-30 |
| NCT05399537Phase 3Vantive Health LLCSafety Evaluation of Prismocitrate 18 in Patients Receiving CRRT | 2027-01 |
| NCT05084196Phase 3Rutgers, The State University of New JerseyMelatonin for Prevention of Kidney Injury | 2027-06-01 |
| NCT07001098Stanford UniversityAmino Acids for Cardiac Surgery Associated AKI | 2026-11 |
| NCT07016074University of MichiganInorganic Nitrate (NaNO3) Prevention of Contrast-Associated Acute Kidney Injury | 2026-11-30 |
Add all 33 to your calendar (.ics) → With an account.
Among the 370 studies in Acute Kidney Injury with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Patients with renal insufficiency who undergo cardiac surgery with cardiopulmonary bypass (CPB) are at significant risk for exacerbation of renal dysfunction postoperatively. This in turn is associated with an increased risk of prolonged intensive care unit (ICU) length of stay, other comorbidities including surgical complications and 30-day mortality. Renal impairment is generally identified based on an increase in serum creatinine concentration and/or a certain magnitude decrease in estimated glomerular filtration rate (eGFR).
The JuxtaFlow® Renal Assist Device (RAD) is designed to sustain or enhance glomerular filtration perioperatively for patients with renal insufficiency by applying a mild controlled negative pressure to the collecting system via the renal pelvis, thereby increasing effective filtration pressure and reducing tubular pressure. This mechanism is designed to support the kidneys' functions during times of renal stress that would be associated with intrarenal edema, volume overload, increased venous pressure, and inflammatory response. By supporting renal function, specifically during the acute stress of CPB, JuxtaFlow holds promise to protect nephron function, decrease renal hypoxia, and provide multifactorial kidney function support to maintain their ability to manage future stress.
1,692 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.
This study's planned enrollment of 124 is above the median of 100 across 819 interventional studies indexed under Acute Kidney Injury.
Browse Acute Kidney Injury studies →3ive Labs is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Compared within Acute Kidney Injury, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Renal Insufficiency. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
To be eligible for participation in this study, an individual must meet all the following criteria:
Female patients of must:
Exclusion Criteria:
An individual who meets any of the following criteria will be excluded from participation in this study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A standard bladder catheter (i.e. Foley) will be placed for bladder urine collection peri-operatively for up to 72 hours while in critical care. No JuxtaFlow catheters will be placed in control subjects.
Subjects randomized to the Treatment group will receive up to 72 hours of controlled negative pressure (-15mmHg) into the renal pelvis of each kidney. Treatment will be discontinued when the subject is transferred out of critical care after at least 24 hours of treatment. A standard bladder catheter (i.e. Foley) will also be placed for bladder urine collection peri-operatively for up to 72 hours.
Device: Renal assist device
The JuxtaFlow RAD includes two endoscopically placed ureteral catheters connected to a bedside pump system. The catheters are designed to deliver a mild, controlled negative pressure (-15 mmHg ± 2mmHg) into the renal pelvis of each kidney for up to 72 hours. This pressure is designed to diffuse through each of the million nephrons lowering intratubular pressure thereby improving the filtration gradient at the glomerulus while supporting overall kidney function.
Also known as: RAD, JuxtaFlow
Mean Peak Percent Change in Serum Creatinine
The mean peak percent change in serum creatinine from baseline values (prior to treatment) within the first 96 hours post-surgery for JuxtaFlow treated subjects as compared to controls.
Time frame: 96 hours peri-operative
Incidence of Treatment-Emergent Adverse Events
The characterization and comparison of all types, frequency, and severity of adverse events (AEs) associated with JuxtaFlow treatment and controls.
Time frame: From enrollment to post-operative day 30
AUC Serum Creatinine
The area under the curve of serum creatinine changes from baseline values (prior to treatment) up to 96 hours post-surgery for JuxtaFlow treated subjects as compared to controls.
Time frame: 96 hours peri-operative
Creatinine Clearance
The average creatinine clearance as a measure of acute glomerular filtration rate, assessed for a minimum of 24 and up to 48 hours in 8-hour intervals during postoperative ICU JuxtaFlow treatment as compared to controls.
Time frame: 24 to 48 hours post-operatively
AKI incidence
The incidence of acute kidney injury (as determined by the KDIGO criteria) during post-surgical hospitalization and 14 days post-surgery with treatment as compared to controls.
Time frame: From post-operative day 1 to 14
Critical Care Length of Stay
The post-surgical critical care length of stay (LOS) in the United States cohort for JuxtaFlow treated subjects as compared to controls.
Time frame: through study study completion, an average of 1 year
AKI severity
The severity and duration of acute kidney injury (as determined by the KDIGO criteria) during post-surgical hospitalization and 14 days post- surgery with treatment as compared to controls.
Time frame: From post-operative day 1 to 14
Urine Electrolytes
The change in urine sodium and potassium excretion rates during the treatment period (up to 72 hours) as compared to controls. Urine output will be assessed in 8-hour intervals perioperatively.
Time frame: Up to 72 hours peri-operatively
eGFR
The change in eGFR (measured by 2021 EPI Cr method) measured at baseline, perioperatively, and at 14- and 30-days post-surgery in JuxtaFlow treated subjects as compared to controls.
Time frame: From enrollment to post-operative day 30
Urine Output
The change in urine output (i.e. volume, urine flow, total oliguria time, total anuria time, etc.) over the course of treatment (up to 72 hours) as compared to controls. Urine output will be assessed in 8-hour intervals perioperatively.
Time frame: Up to 72 hours peri-operatively
Hospital Length of Stay
The post-surgical hospital length of stay (LOS) in the United States cohort for JuxtaFlow treated subjects as compared to controls.
Time frame: through study study completion, an average of 1 year
Anemia Incidence
The incidence of anemia (as defined by a nadir hematocrit below 23% for women and 28% for men after initiating the investigational treatment) assessed immediately after starting treatment, immediately after surgery, and at every postoperative 8-hour period during treatment (up to 72-hours) after initiation of the treatment, and daily during the post-treatment period (until hospital discharge) as compared to controls.
Time frame: through study study completion, an average of 1 year
Electrolyte abnormalities
The incidence of electrolyte abnormalities (as defined by any alteration in the metabolic panel according to the reference values after initiating the investigational treatment) assessed immediately after starting JuxtaFlow treatment, immediately after surgery, and at every postoperative 8-hour period during treatment (up to 72-hours) after initiation of the investigational treatment, and daily during the post-treatment period (until hospital discharge). Assessed by comprehensive metabolic panel (includes calcium, sodium, potassium and carbon dioxide) and excretion rates calculated from a Urinalysis panel (includes sodium and potassium).
Time frame: through study study completion, an average of 1 year
Azotemia
The incidence of azotemia or elevated blood urea nitrogen (BUN).
Time frame: through study study completion, an average of 1 year
Dialysis Incidence
The incidence of dialysis within 30 days post-surgery.
Time frame: From post-operative day 1 to 30
Hospital Readmission
Readmission to in-patient hospitalization for any reason within the 30- day postoperative period.
Time frame: From post-operative day 1 to 30
Mortality
All-cause mortality at 30 days post-surgery.
Time frame: From post-operative day 1 to 30
Not enrolling at this site.
Plan to share: Undecided
Started Jul 2025 (actual). Primary completion is estimated for Dec 2026, 17 months after the start.
Of 269 interventional studies with no phase under Acute Kidney Injury, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 44. This study's planned 17 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.